Evidence map›Paper›PMID 33300074›Full record

ArticleMolecular medicine reports2021

[Retracted] MicroRNA‑21 increases cell viability and suppresses cellular apoptosis in non‑small cell lung cancer by regulating the PI3K/Akt signaling pathway.

Tao Wang, Zhenyu Cai, Guolin Hong, Gangsen Zheng, Yu Huang, Shun Zhang, Jinhua Dai

Abstract readRetraction Notice
In one paragraph

Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Tao WangDepartment of Clinical Laboratory, The First Affiliated Hospital of Xiamen University, Fujian Medical University, Xiamen, Fujian 361003, P.R. China.
Zhenyu CaiDepartment of Anesthesiology, The First Affiliated Hospital of Xiamen University, Fujian Medical University, Xiamen, Fujian 361003, P.R. China.
Guolin HongDepartment of Clinical Laboratory, The First Affiliated Hospital of Xiamen University, Fujian Medical University, Xiamen, Fujian 361003, P.R. China.
Gangsen ZhengDepartment of Clinical Laboratory, The First Affiliated Hospital of Xiamen University, Fujian Medical University, Xiamen, Fujian 361003, P.R. China.
Yu HuangDepartment of Clinical Laboratory, The First Affiliated Hospital of Xiamen University, Fujian Medical University, Xiamen, Fujian 361003, P.R. China.
Shun ZhangStem Cell and Regenerative Medicine Laboratory, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315010, P.R. China.
Jinhua DaiDepartment of Clinical Laboratory, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315010, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the publication of this paper, the authors have contacted the Editorial Office to request that their article be retracted. The reason for this retraction is an inability to be able to replicate certain of their previous results, and also disagreements among the authors as to the interpretation of some of the data. Following further discussion, all authors and the Editor of Molecular Medicine Reports are in agreement that the paper should be retracted; moreover, the authors apologize to the readership for any inconvenience caused. [the original article was published in Molecular Medicine Reports 16: 6506‑6511, 2017; DOI: 10.3892/mmr.2017.7440].

Identifiers

PMID33300074
PMCPMC7751454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.